Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Aug;43(8):1948-1957.
doi: 10.2337/dc19-2419.

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Sushrima Gan  1 , Adem Y Dawed  1 , Louise A Donnelly  1 , Anand T N Nair  1 , Colin N A Palmer  1 , Viswanathan Mohan  2 , Ewan R Pearson  3
Affiliations
Meta-Analysis

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Sushrima Gan et al. Diabetes Care. 2020 Aug.

Abstract

Background: The pathophysiology of type 2 diabetes differs markedly by ethnicity.

Purpose: A systematic review and meta-analysis was conducted to assess the impact of ethnicity on the glucose-lowering efficacy of the newer oral agents, sodium-glucose cotransporter 2 inhibitors (SGLT-2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), and dipeptidyl peptidase 4 inhibitors (DPP-4i), using evidence from randomized clinical trials (RCTs).

Data sources: A literature search was conducted in PubMed of all randomized, placebo-controlled trials of DPP-4i, SGLT-2i, and GLP-1RA. The search strategy was developed based on Medical Subject Headings (MeSH) terms and keywords.

Study selection: A total of 64 studies that qualified for meta-analysis after full-text review based on predefined inclusion and exclusion criteria-RCTs with at least 50 patients in each arm, >70% of population from Asian or white group, duration ≥24 weeks, and publication up to March 2019-were selected for systematic review and meta-analysis.

Data extraction: Data extraction was done for aggregated study-level data by two independent researchers. Absolute changes in HbA1c (%) from baseline to 24 weeks between the drug and placebo were considered as the primary end point of the study.

Data synthesis: Change in HbA1c was evaluated by computing mean differences and 95% CIs between treatment and placebo arms.

Limitations: The study is based on summarized data and could not be separated based on East Asians and South Asians.

Conclusions: The glucose-lowering efficacy of SGLT-2i, and to a lesser extent DPP-4i, was greater in studies of predominantly Asian ethnicity compared with studies of predominantly white ethnicity. There was no difference seen by ethnicity for GLP-1RA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Forest plot for white- and Asian-dominant groups for DPP-4i. See references – for complete citations.
Figure 2
Figure 2
Forest plot for white- and Asian-dominant groups for SGLT-2i. See references – for complete citations.
Figure 3
Figure 3
Forest plot for white- and Asian-dominant groups for GLP-1RA. See references , – for complete citations.
See this image and copyright information in PMC

Comment in

References

    1. Cho NH, Shaw JE, Karuranga S, et al. . IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271–281 - PubMed
    1. Afroz A, Ali L, Karim MN, et al. . Glycaemic control for people with type 2 diabetes mellitus in Bangladesh - an urgent need for optimization of management plan. Sci Rep 2019;9:10248. - PMC - PubMed
    1. Davies MJ, D’Alessio DA, Fradkin J, et al. . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–2701 - PMC - PubMed
    1. Jude EB, Nixon M, O’Leary C, et al. . Evaluating glycemic control in patients with type 2 diabetes suboptimally controlled on basal insulin: UK ATTAIN Real-World Study. Diabetes Ther 2019;10:1847–1858 - PMC - PubMed
    1. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535–1540 - PubMed

Publication types

MeSH terms

Substances